{"url_path":"/sec/lxeo/8-k/2026-06-29/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-29","source_url":"https://www.sec.gov/Archives/edgar/data/1907108/0001193125-26-288703-index.html","accession_number":"0001193125-26-288703","cik":"0001907108","ticker":"LXEO","issuer_name":"Lexeo Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1907108/0001193125-26-288703-index.html","primary_entity_key":"0001907108","primary_entity_name":"Lexeo Therapeutics, Inc."},"word_count":252,"has_tables":true,"body_markdown":"## Item 5.07 Submission of Matters to a Vote of Security Holders.\n\nOn June 25, 2026, Lexeo Therapeutics, Inc. (the “Company”) held its virtual 2026 Annual Meeting of Stockholders (the “Annual Meeting”) exclusively online via live webcast. The stockholders voted on the following proposals at the Annual Meeting:\n\nProposal 1. Election of Class III Directors\n\nThe Company’s stockholders elected the persons listed below as Class III Directors, to serve until the Company’s 2029 Annual Meeting of Stockholders and until their respective successors are elected and qualified, or until their earlier death, resignation or removal. The final voting results are as follows:\n\nFOR\n\nWITHHELD\n\nBROKER NON-VOTE\n\nR. Nolan Townsend\n\n64,731,479\n\n895,808\n\n9,955,777\n\nBrenda Cooperstone, M.D.\n\n48,792,570\n\n16,834,717\n\n9,955,777\n\nPaula HJ Cholmondeley\n\n64,652,712\n\n974,575\n\n9,955,777\n\nProposal 2. Ratification of Appointment of Independent Registered Public Accounting Firm\n\nThe Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows:\n\n \n\n \n\nFOR\n\nAGAINST\n\nABSTAIN\n\n \n\n75,497,386\n\n55,579\n\n30,099\n\nFor more information about the foregoing proposals, see the Proxy Statements filed with the Securities and Exchange Commission on April 30, 2026.\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nLexeo Therapeutics, Inc.\n\n \n\n \n\n \n\n \n\nDate:\n\nJune 29, 2026\n\nBy:\n\n/s/ R. Nolan Townsend\n\n \n\n \n\n \n\nR. Nolan Townsend, Chief Executive Officer"}